“Too small to succeed?” Rethinking efficacy claims in a solriamfetol trial for ME/CFS

Bellomo R Warrillow SJ Reade MC (2009) Why we should be wary of single-center trials. Critical Care Medicine 37(12): 3114–3119.

Ioannidis JPA (2005) Why most published research findings are false. PLoS Medicine 2(8): e124.

Kim DY Lee JS Park SY , et al. (2020) Systematic review of randomized controlled trials for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). Journal of Translational Medicine 18: 7.

Mosher CE Secinti E Johns SA , et al. (2022) Comparative responsiveness and minimally important difference of Fatigue Symptom Inventory (FSI) scales and the FSI-3 in trials with cancer survivors. Journal of Patient-Reported Outcomes 6: 82.

Parker RA Weir CJ (2022) Multiple secondary outcome analyses: Precise interpretation is important. Trials 23: 27.

Shwartz SK Roper BL Arentsen TJ , et al. (2020) The Behavior Rating Inventory of Executive Function®-Adult Version is related to emotional distress, not executive dysfunction, in a veteran sample. Archives of Clinical Neuropsychology 35(6): 701–716.

Sigurdardottir S von der Lippe C Media L , et al. (2023) Self-reported symptoms of everyday executive dysfunction, daytime sleepiness, and fatigue and health status among adults with congenital aniridia: A descriptive study. Health Psychology and Behavioral Medicine 11(1): 2263534.

Vadillo MA Konstantinidis E Shanks DR (2016) Underpowered samples, false negatives, and unconscious learning. Psychonomic Bulletin & Review 23: 87–102.

Young JL Powell RN Powell A , et al. (2025) Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after 8 weeks of treatment. Journal of Psychopharmacology. Epub ahead of print 16 September 2025. DOI: 10.1177/02698811251368371.